Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN
Vertex Pharmaceuticals (Australia) Pty.
Severe sickle cell disease (SCD)
1 trial -
Cenerimod
Viatris Pharmaceuticals Co.,
Lupus Erythematosus, Systemic
2 trials -
Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Systemic lupus erythematosus
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671
Sanofi-aventis Healthcare Pty Ltd
Gaucher's disease type III
1 trial -
Chemotherapy
International Peace Maternity and Child Health Hospital
Non Small Cell Lung Cancer
1 trial -
Cholic Acid
Mirum Pharmaceuticals International B.V.
Bile Acid Synthesis Defect
1 trial -
Cholic Acids
Mirum Pharmaceuticals International B.V.
Infantile Refsum's Disease
1 trial -
Cholic acid
Mirum Pharmaceuticals International B.V.
Inborn Errors of Bile Acid Synthesis
1 trial -
Cibinqo 100 mg film-coated tablets, Placebo for Abrocitinib 100mg tablet
Pfizer Australia Pty Ltd
Moderate to severe atopic dermatitis
1 trial -
Cilostazol-Elpen 100 mg Tabletten, Placebo de Cilostazol-Elpen 100mg, comprimΓ©
Pari Pharma GmbH
Aneurysmal Subarachnoid Hemorrhage
1 trial -
Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets
AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
Clascoterone
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acne Vulgaris
1 trial -
Class I or III Antiarrhythmic Medications
Rhythm Pharmaceuticals Netherlands B.V.
Atrial Fibrillation
1 trial -
Clifutinib
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Leukemia, Acute Myeloid (AML)
1 trial -
Colchicine 0.5 mg
The George Institute
Intracerebral Hemorrhage
1 trial -
Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106
Inhibrx Biosciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Conceptrol
Evofem Biosciences
Contraception
1 trial -
Conivaptan hydrochloride
CUMBERLAND PHARMACEUTICALS INC
Hyponatremia
1 trial -
Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal productsβ (IMP) formulation. The resulting product is a suspension.
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.
1 trial -
Coronary artery bypass grafting
Rhythm Pharmaceuticals Netherlands B.V.
Ischemic Heart Failure
1 trial -
Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules
NEUROCRINE BIOSCIENCES INC
Classic Congenital Adrenal Hyperplasia (CAH)
1 trial -
Cyproterone acetate
Takeda
Adenocarcinoma, Prostate
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources